A kind of new medicine cube benzene phthalein in our country finishes three clinical trials

A kind of new medicine cube benzene phthalein in our country finishes three clinical trials
A kind of new medicine cube benzene phthalein in our country finishes three clinical trials
The reporter Wang Dan learns at the national neurological annual meeting on the 12th held in Beijing from October 15 to 17, regarded as a first a kind of new medicine of chemistry which is short of blood infarction of brain of treatment with the independent intellectual property right in our country, man benzene phthalein parenteral solution has already finished three clinical trials. The result verifies it is used for treating the curative effect of infarction of acute brain precisely, the incidence of bad reaction is low, security is better. It is introduced, man benzene phthalein is that 3rd in our country has chemical medicine of the totally independent intellectual property right. Animal's experiment indicates, man benzene phthalein improves and circulates, protects mitochondria,etc. function a little, can increase patient's brain blood flow volume in the ischemic district effectively, improve the brain district to circulate a little; Improve the whole energy supersession under ischemic brain, inhibit cells from withering and dying, lighten the intensity that the neural function damages at the same time. The presidents of this conference, Chinese Medical Association's neuropathy credit are known to the nerve head of the department of internal medicine Professor Cui LiYing of General Board, BJ Union Hospital and said, this time three clinical trials take many centres, research approach contrasted in a pair of blind, a pair of simulation at random, pitch the intersection of Grey and the intersection of sodium and parenteral solution for contrast product with, include patient in 552 people altogether, man the intersection of benzene and the intersection of phthalein and group and it pitches Grey to be 370 people and 182 people respectively in the intersection of sodium and group among them. Researchers mark (NIHSS) the state-run nerve function defect of commune hospital in U.S.A. in 8 days, 15 days after and use medicine to two groups of patients in 0 daysing , Barthel index (BI) directed against daily viability Grade, to directing against Rankin scale (mRS) of daily viability on the 30th day, 90 days after all patient treatments Grade. Result use man benzene the intersection of phthalein and patient of parenteral solution NIHSS grade, reveal the intersection of nerve and the intersection of function and improvement of defect, patient of experimental group, obviously superior to the control group at the 15 day; MRS for 90 days grades to reveal, the viability of patient of experimental group is obviously superior to the control group. Meanwhile, weigh with the above-mentioned index, the curative effect of experimental group is superior to the control group, the incidence of bad reaction does not have a statistics difference compared with control group. In addition, the patient continues using man benzene phthalein in acute brain infarction convalescence, can further promote the neural function of the ischemic patient of brain to resume, improve patient's working and viability. Led by BJ Union Hospital this clinical trial, 37 clinical pharmacology centres in the whole country participate in. It is reported, man benzene phthalein capsule has already launched two, three, four clinical research in our country since 1998; From the 2003, man the intersection of benzene and the intersection of phthalein and parenteral solution start the first stage of clinical trial in 3 issues.


|